Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Drug Design Methodologies
AddedFeb 17, 2024
UpdatedJun 18, 2026
Drug Design Methodologies

Drug Design Methodologies

Angel

Developing advanced software for efficient, cost-effective, and risk-free structure-based drug design in pharma and biotech.

HQ
St. Louis, MO, US
Founded
1998
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to revolutionize drug discovery, Drug Design Methodologies develops cutting-edge computational software for structure-based drug design. Their core vision is to streamline and enhance the drug development process by chemically optimizing and accurately measuring drug-target binding. The company's innovative software identifies promising drug candidates and eliminates compounds with potential off-target effects, thereby accelerating and de-risking pharmaceutical and biotechnology pipelines while reducing costs.

Notable affiliations include partnerships with leading pharmaceutical companies and biotech firms. The company has achieved significant milestones, including the successful integration of their software into several high-profile drug development projects. By reducing the time and financial investment required for drug discovery, Drug Design Methodologies has made a substantial impact on the industry, facilitating the development of safer and more effective therapeutic solutions.

Drug Design Methodologies - Similar Companies

PathDrugomics logo

PathDrugomics

Design Pharmaceuticals logo

Design Pharmaceuticals

Schrödinger logo

Schrödinger

schrodinger.com

QuantumBio logo

QuantumBio

quantumbioinc.com

Cloud Pharmaceuticals logo

Cloud Pharmaceuticals

BioLeap logo

BioLeap

GeneCentrix logo

GeneCentrix

genecentrix.com

Rasio Therapeutics logo

Rasio Therapeutics

rasiotx.com

Atommap logo

Atommap

Confluence Discovery Technologies logo

Confluence Discovery Technologies

Nanome logo

Nanome

nanome.ai

Insitro logo

Insitro

insitro.com

Pythia Labs logo

Pythia Labs

pythialabs.com

XtalPi logo

XtalPi

xtalpi.com

Insightful Science logo

Insightful Science

Drug Design Methodologies - Quick Facts

Who are Drug Design Methodologies' competitors?

Companies similar to Drug Design Methodologies include PathDrugomics, Design Pharmaceuticals, Schrödinger and QuantumBio.

When was Drug Design Methodologies founded?

Drug Design Methodologies was founded in 1998.

Where is Drug Design Methodologies' headquarters located?

Drug Design Methodologies' headquarters is located in St. Louis, MO, US.

When was Drug Design Methodologies' last funding round?

Drug Design Methodologies' most recent funding round was for $50k (USD) in November 2017.

How much has Drug Design Methodologies raised to-date?

As of Nov 4, 2017, Drug Design Methodologies has raised a total of $50k (USD).

How many employees does Drug Design Methodologies have?

Drug Design Methodologies has 2 employees as of Feb 4, 2024.

Drug Design Methodologies - Classification

Ownership
  • Private
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
  • Small Business
Main Product
  • Drug Design
  • Software
Tags
  • Biotech
  • SaaS
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software